The potential benefits of gene-targeted therapy have been studied for SCLC, and recent work showing the frequent occurrence of genomic TP73 alterations in SCLC indicates that there are potentially promising targets in SCLC tumors [52]. This evidence concerns the gene TP73 and small cell lung carcinoma.